Sandra Close
6 Papers
Sandra Close is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design
Mark Roschewski,David M. Kurtz,Jason R. Westin,Ryan C. Lynch,Charles Macaulay,Christian Kuffer,Gregory J. Hogan,Sandra Close,Jacob J. Chabon,Davide Rossi,Maximilian Diehn,Ash A. Alizadeh,Andre Schultz +12 more
9
Mrd‐negativity after frontline dlbcl therapy: pooled analysis of 6 clinical trials
Mark Roschewski,David M. Kurtz,Jason R. Westin,Ryan C. Lynch,Stefan Alig,Charles Macaulay,Christian Kuffer,Gregory J. Hogan,Andre Schultz,Sandra Close,Jacob J. Chabon,D. Rossi,Stephen Opat,Rod Hicks,Mark Hertzberg,Maximilian Diehn,Walter Walter Wilson,Ash A. Alizadeh +17 more
TL;DR: Kurtz et al. as mentioned in this paper integrated PhasED-Seq MRD from LBCL studies using curative intent 1st-line regimens to predict future PFS events, with lead times up to 30 mo before radiologic PD.
2
Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy
Jordan S. Goldstein,W. Kim,Sang Eun Yoon,Seok Jin Kim,Mark Roschewski,J. Westin,Ryan C. Lynch,Stefan Alig,Sandra Close,Jacob J. Chabon,Davide Rossi,Wyndham H. Wilson,Maximilian Diehn,Ash A. Alizadeh,David M. Kurtz +14 more
TL;DR: The power of ctDNA to predict progression free survival (PFS) at 24 months improved later in therapy, with area under the receiver operator curves (AUROCs) for PFS24 improved laterIn therapy, as well as generating patient-specific log-linear models assuming exponential decay.
2
Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
David M. Kurtz,Gregory J. Hogan,Andre Schultz,Katerina Kopeckova,Christian Kuffer,Derek Blair,Steve Wagner,Sandra Close,Maximilian Diehn,Jacob J. Chabon,Ash A. Alizadeh,Jason R. Westin +11 more
TL;DR: Kurtz et al. as mentioned in this paper proposed an analytical sensitivity of minimal residual disease (MRD) detection by PhasED-Seq to track response and predict curative outcomes after first-line (1L) therapy.
1
Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study
Brian Sworder,Sang Eun Yoon,Seok Jin Kim,Andre Schultz,Gregory J. Hogan,Sandra Close,Jacob J. Chabon,Maximilian Diehn,David M. Kurtz,Ash A. Alizadeh,W. Kim +10 more
TL;DR: Longitudinally measured ctDNA levels, without use of tumor biopsies, in a real-world population of DLBCL patients treated with curative intent using current anthracycline-based induction regimens are reported to be prognostic for both PFS and OS.